{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'Committees Structure', 'A study charter will be created to describe important governance aspects while the', 'study is being conducted.', 'The SRT will include the Safety Development Leader, GCSP scientist, MM, CIL', 'and study statistician but will extend to other functions as requied. The SRT will', 'provide a proactive, aggregate and holistic evaluation of the safety data of', 'danirixin. Further details are included in the SRT charter.', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. If', 'this is foreseen, the investigator agrees to submit all manuscripts or abstracts to', 'the sponsor before submission. This allows the sponsor to protect proprietary', 'information and to provide comments.', 'The sponsor will comply with the requirements for publication of study results.', 'In accordance with standard editorial and ethical practice, the sponsor will', 'generally support publication of multicenter studies only in their entirety and not', 'as individual site data. In this case, a coordinating investigator will be', 'designated by mutual agreement.', 'Authorship will be determined by mutual agreement and in line with', 'International Committee of Medical Journal Editors authorship requirements.', 'Dissemination of Clinical Study Data', 'This study will be registered and study information from this protocol will be', 'posted on publicly available clinical trial registers before enrolment of study', 'participants begins.', 'The results summary of this study will be posted to the GSK Clinical Study', 'Register and other publicly available clinical trial registers within 8 months of', 'the primary study completion date.', 'A manuscript reporting the study results will be submitted to a peer reviewed', \"journal within 18 months of the last participant's last visit.\", 'Data Quality Assurance', 'All participant data relating to the study will be recorded on printed or electronic', 'CRF unless transmitted to the sponsor or designee electronically (eg, laboratory', 'data). The investigator is responsible for verifying that data entries are accurate', 'and correct by physically or electronically signing the CRF.', 'The investigator must maintain accurate documentation (source data) that', 'supports the information entered in the CRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review,', 'and regulatory agency inspections and provide direct access to source data', 'documents.', '63']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'The sponsor or designee is responsible for the data management of this study', 'including quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that', 'data entered into the CRF by authorized site personnel are accurate, complete,', 'and verifiable from source documents; that the safety and rights of participants', 'are being protected; and that the study is being conducted in accordance with the', 'currently approved protocol and any other study agreements, ICH GCP, and all', 'applicable regulatory requirements.', 'Records and documents, including signed ICF, pertaining to the conduct of this', 'study must be retained by the investigator for 25 years after study completion', 'unless local regulations or institutional policies require a longer retention period.', 'No records may be destroyed during the retention period without the written', 'approval of the sponsor. No records may be transferred to another location or', 'party without written notification to the sponsor.', 'Source Documents', 'Source documents provide evidence for the existence of the participant and', 'substantiate the integrity of the data collected. Source documents are filed at the', \"investigator's site.\", 'Data reported on the CRF or entered in the eCRF that are transcribed from', 'source documents must be consistent with the source documents or the', 'discrepancies must be explained. The investigator may need to request previous', 'medical records or transfer records, depending on the study. Also, current', 'medical records must be available.', 'Definition of what constitutes source data can be found in the SRM.', 'Study and Site Closure', 'GSK or its designee reserves the right to close the study site or terminate the study at any', 'time for any reason at the sole discretion of GSK. Study sites will be closed upon study', 'completion. A study site is considered closed when all required documents and study', 'supplies have been collected and a study-site closure visit has been performed.', 'The investigator may initiate study-site closure at any time, provided there is reasonable', 'cause and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the sponsor or investigator may include', 'but are not limited to:', 'Failure of the investigator to comply with the protocol, the requirements of the', \"IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines\", 'Inadequate recruitment of participants by the investigator', 'Discontinuation of further study treatment development', '64']\n\n###\n\n", "completion": "END"}